Search company, investor...

Stage

Unattributed - II | Alive

Total Raised

$2.88M

Last Raised

$2.38M | 4 yrs ago

About Novuson Surgical

Novuson produces automatic devices that use focused ultrasound energy for fast and robust hemostasis, cauterization, and ablation. The devices cauterize tissue from the inside out, creating a well-defined, controlled plane of cauterization. This enables clinicians to treat or remove tumors quickly and effectively on solid organs, tissue up to 5cm thick, and highly vascularized tissues without bleeding complications.

Headquarters Location

11824 North Creek Parkway N. Suite 103

Bothell, Washington, 98011,

United States

425-481-7165

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Novuson Surgical Patents

Novuson Surgical has filed 4 patents.

The 3 most popular patent topics include:

  • Acoustics
  • Medical equipment
  • Medical ultrasonography
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2017

3/1/2022

Medical ultrasonography, Ultrasound, Medical equipment, Acoustics, Telescope types

Grant

Application Date

10/18/2017

Grant Date

3/1/2022

Title

Related Topics

Medical ultrasonography, Ultrasound, Medical equipment, Acoustics, Telescope types

Status

Grant

Latest Novuson Surgical News

Novuson® Surgical Secures Funding from HOYA Corporation

May 28, 2019

0 Message : *Required fields BOTHELL, Wash., May 28, 2019 /PRNewswire/ -- Novuson Surgical, a Bothell, WA based medical device company, has secured funding from HOYA Corporation to finalize development for the UltraStat 3mm Vessel Sealer / Divider using Direct Therapeutic Ultrasound (DTU). DTU is a novel approach using a therapeutic modality of ultrasound in the first substantive innovation in advanced energy surgical devices in decades. The UltraStat is applicable in Urologic, Pediatric, Gynecologic, Bariatric, Trauma and other surgical specialties. "We are excited to partner with HOYA Corporation, their funding will provide necessary capital to finalize our commercial development enabling Novuson to submit our launch product, the UltraStat 3mm Mini LS, for our first 510k Clearance with the FDA by the end of this year," said Stuart B. Mitchell, PhD, CEO & Founder of Novuson. "This investment into Novuson Surgical demonstrates HOYA's committed involvement in the development of novel laparoscopic medical devices. We look forward to working with the Novuson team to improve clinical outcomes for patients with this advancement in ultrasonic laparoscopic devices," said Rubal Bedi, Global Head, Vice-President of Corporate Venture Capital. As part of the investment, James M. Kaiser, Director of Corporate Venture Capital will be joining Novuson as a board member. About Novuson Surgical: Novuson Surgical is a privately held company based in Bothell, WA. Novuson Surgical's patented technology delivers Direct Therapeutic Ultrasound (DTU) energy for cauterization and hemostatic control without transmission of electricity through the patient and provides safety and predictability in the most critical surgical applications. For more information, please visit: www.novuson.com    About Hoya: Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people. For more information, please visit:  http://www.hoya.com Contact: Shane D. Cerrato, Novuson Surgical, Inc., EVP of Business Development, T: +1.916.803.6487, 425.481.7165, scerrato@novuson.com   or Stuart B Mitchell, Novuson Surgical, Inc., CEO, T: 425.238.6227, sbmitchell@novuson.com .

Novuson Surgical Frequently Asked Questions (FAQ)

  • Where is Novuson Surgical's headquarters?

    Novuson Surgical's headquarters is located at 11824 North Creek Parkway N., Bothell.

  • What is Novuson Surgical's latest funding round?

    Novuson Surgical's latest funding round is Unattributed - II.

  • How much did Novuson Surgical raise?

    Novuson Surgical raised a total of $2.88M.

  • Who are the investors of Novuson Surgical?

    Investors of Novuson Surgical include HOYA.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.